急性髓系白血病预后因素的评估。前言。 - Suppr

Evaluation of prognostic factors in AML. Preface.

作者信息

Rowe Jacob M

出版信息

Best Pract Res Clin Haematol. 2011 Dec;24(4):485-8. doi: 10.1016/j.beha.2011.09.003. Epub 2011 Nov 15.

DOI:10.1016/j.beha.2011.09.003

PMID:22127310

Abstract

摘要

相似文献

Evaluation of prognostic factors in AML. Preface.

Best Pract Res Clin Haematol. 2011 Dec;24(4):485-8. doi: 10.1016/j.beha.2011.09.003. Epub 2011 Nov 15.

Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.

Ann Hematol. 2012 Dec;91(12):1871-7. doi: 10.1007/s00277-012-1528-9. Epub 2012 Jul 21.

New agents: great expectations not realized.

Best Pract Res Clin Haematol. 2013 Sep;26(3):269-74. doi: 10.1016/j.beha.2013.10.007. Epub 2013 Oct 16.

A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.

Br J Haematol. 2016 Sep;174(5):700-10. doi: 10.1111/bjh.14107. Epub 2016 Apr 26.

Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.

Clin Adv Hematol Oncol. 2008 Nov;6(11):3-5.

Overall survival in acute myeloid leukaemia patients with and without internal tandem duplication.

Asian Pac J Cancer Prev. 2015;16(1):393. doi: 10.7314/apjcp.2015.16.1.393.

Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.

Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18.

Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.

Leuk Lymphoma. 2019 Nov;60(11):2844-2846. doi: 10.1080/10428194.2019.1608532. Epub 2019 May 3.

Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1399-406. doi: 10.1016/j.bbmt.2014.05.019. Epub 2014 May 28.

Are immunoconjugates approaching "standard of care" in AML?

Best Pract Res Clin Haematol. 2013 Sep;26(3):261-8. doi: 10.1016/j.beha.2013.10.006. Epub 2013 Oct 16.

引用本文的文献

Venetoclax-containing regimens in acute myeloid leukemia.

Ther Adv Hematol. 2021 Feb 11;12:2040620720986646. doi: 10.1177/2040620720986646. eCollection 2021.

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

Leuk Lymphoma. 2014 Oct;55(10):2301-4. doi: 10.3109/10428194.2013.877134. Epub 2014 Feb 24.

Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?

Curr Hematol Malig Rep. 2013 Jun;8(2):109-15. doi: 10.1007/s11899-013-0157-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evaluation of prognostic factors in AML. Preface.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献